Every 10-Q that Iridex Corp (IRIX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IRIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRIX filings page.
IRIDEX Corporation (IRIX) reported lower revenue but a smaller net loss for the three and six months ended July 4, 2026. Quarterly revenue was $12.6 million, down 7.4% year over year, with Cyclo G6 glaucoma products growing while retina product revenue declined. Gross margin was 34.2%, slightly below 34.5% a year earlier, as higher manufacturing and tariff-related costs weighed on profitability. The company posted a quarterly net loss of $1.3 million (–$0.07 per share), compared with a $1.0 million loss in the prior-year quarter; year-to-date loss improved to $1.8 million from $2.7 million.
Cash and cash equivalents were $4.7 million with working capital of $10.8 million, against total liabilities of $23.6 million, including a $3.8 million convertible note. Deferred revenue totaled $8.2 million, largely from a 10‑year exclusive distribution arrangement with Topcon, which accounted for about 30–33% of revenue. Management highlights ongoing cost-control initiatives, a continued shift to lower-cost contract manufacturers, and macroeconomic and geopolitical uncertainty affecting capital equipment demand.
IRIDEX Corporation reported a smaller quarterly loss on essentially flat revenue. For the three months ended April 4, 2026, revenue was $11.8 million versus $11.9 million a year earlier, as higher glaucoma and "other" sales offset lower retina product revenue.
Gross profit declined to $4.7 million and gross margin slipped to 40.2% from 42.5%, mainly from higher manufacturing and tariff-related costs during a transition to lower-cost contract manufacturers. Operating expenses fell slightly, with general and administrative costs down due to lower consulting and deal-related legal spending.
Net loss improved to $0.5 million from $1.7 million, helped by the absence of the prior-year $1.3 million loss on extinguishment of a convertible note. Cash and cash equivalents were $4.6 million and working capital was $11.8 million at quarter end. Management believes existing liquidity is sufficient for at least the next 12 months.
IRIDEX (IRIX) reported Q3 2025 results showing total revenues of $12.484M, up from $11.581M a year ago. Gross profit was $4.013M versus $4.323M last year, with a loss from operations of $1.411M improving from $1.870M. Net loss narrowed to $1.573M from $1.933M, as operating expenses declined year over year.
By product, Retina delivered $6.698M and Cyclo G6 $3.537M. The United States contributed $5.588M; EMEA reached $4.033M. A key distributor, Topcon, accounted for 31% of Q3 revenues.
Cash and cash equivalents were $5.573M at quarter‑end (vs. $2.387M at December 28, 2024), aided by $6.0M of Series B convertible preferred stock and a $4.0M convertible note, partially offset by repayment of a prior note. The company recorded a year‑to‑date loss on extinguishment of debt of $1.335M and an inventory write‑down of $0.823M. Deferred revenue ended at $9.416M, including exclusivity fees recognized at $0.4M in Q3.
Total stockholders’ equity increased to $4.681M from $2.097M. Common shares outstanding were 17,189,981 as of November 6, 2025.
IRIDEX Corporation reported quarterly revenue of $13.6 million (up 7.4% year-over-year) and six-month revenue of $25.5 million (up 4.4%). Gross margin for the quarter was 34.5% versus 40.7% a year earlier, and six-month gross margin was 38.2%. The company recorded a net loss of $0.99 million for the quarter and $2.68 million for the six-month period. Cash and cash equivalents rose to $6.8 million and working capital was $13.2 million, supported by financing activity.
The company completed financings including issuance of 600,000 Series B preferred shares for $6.0 million and a $4.0 million convertible note; it also recognized a $1.3 million loss on extinguishment of a prior convertible note. Topcon remains a material related-party customer, representing ~32% of quarterly revenue and ~29% of accounts receivable. Inventories were $8.4 million and deferred revenue ended at $9.9 million.